Overview of Advanced Ovarian Cancer Treatment
Author Information
Author(s): MRC Gynaecological Cancer Working Party
Primary Institution: MRC Cancer Trials Office
Hypothesis
Is combination chemotherapy more effective than single-agent therapy for advanced ovarian cancer?
Conclusion
The overview aims to clarify the survival benefits of different chemotherapy treatments for advanced ovarian cancer.
Supporting Evidence
- 85% of ovarian cancer patients die from the disease.
- 5-year survival rates drop from 50-70% in early stages to 5-10% in advanced stages.
- Only three out of 39 trials showed a significant survival advantage for combination chemotherapy.
Takeaway
Doctors are trying to figure out the best way to treat advanced ovarian cancer by looking at many studies together.
Methodology
The study proposes an overview of all relevant randomized trials to assess the survival benefits of different chemotherapy treatments.
Potential Biases
There is a risk of publication bias, as studies with positive results are more likely to be published.
Limitations
Many individual trials are small, making it hard to detect moderate survival differences.
Participant Demographics
Approximately 5,000 patients treated annually in the UK.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website